×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| GLAXOSMITHKLINE PHARMACEUTICAL | 8485.9 | 2047.0 | 8048.3 | 12.08 | 47,280 | 49.9 |
| Cohance Lifesciences Limited | 4966.8 | 525.7 | 4835.8 | 1.37 | 38752 | 110.0 |
| Global Health Limited | 9052.95 | 1519.64 | 8821.56 | 5.65 | 37386 | 65.6 |
GlaxoSmithkline Pharmaceuticals Ltd., with Security Code 500660, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 782.2 | 738.0 | 953.4 | 805.0 | 910.9 | 811.0 | 1,000.1 | 946.4 | 966.1 | 804.8 |
| Expenses | 615.4 | 596.8 | 666.8 | 587.5 | 655.6 | 581.6 | 681.1 | 656.2 | 635.3 | 554.1 |
| Operating Profit | 166.8 | 141.3 | 286.6 | 217.5 | 255.3 | 229.4 | 319.0 | 290.2 | 330.8 | 250.8 |
| OPM % | 21.32% | 19.14% | 30.06% | 27.02% | 28.03% | 28.29% | 31.89% | 30.66% | 34.24% | 31.16% |
| Other Income | 38.4 | 54.1 | 28.5 | -135.0 | 32.3 | 35.9 | 36.9 | 35.1 | 39.5 | 43.8 |
| Interest | 0.7 | 0.3 | 0.4 | 0.3 | 0.8 | 0.4 | 0.3 | 0.1 | 0.6 | 0.4 |
| Depreciation | 17.2 | 16.4 | 18.1 | 17.1 | 18.1 | 16.4 | 16.9 | 18.8 | 14.7 | 15.5 |
| Profit before tax | 176.9 | 161.4 | 296.5 | 228.4 | 266.3 | 248.5 | 334.0 | 306.4 | 354.9 | 278.6 |
| Tax % | -29.8% | -26.9% | -27.3% | -30.1% | -28.1% | -26.9% | 26.6% | 25.4% | -26.7% | 26.5% |
| Net Profit | 131.5 | 130.6 | 215.5 | 45.5 | 193.1 | 181.7 | 248.7 | 228.6 | 260.1 | 204.7 |
| EPS in Rs | 7.77 | 7.71 | 12.72 | 2.69 | 11.39 | 10.72 | 14.68 | 13.49 | 0 | 12.08 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 802.3 | 787.5 | 761.7 | 957.0 | 805.3 | 929.8 | 814.7 | 1,010.8 | 949.4 | 974.4 |
| Expenses | 573.6 | 617.7 | 617.8 | 667.5 | 587.2 | 672.5 | 584.1 | 689.1 | 657.5 | 641.1 |
| Operating Profit | 228.7 | 169.7 | 143.9 | 289.5 | 218.1 | 257.3 | 230.5 | 321.7 | 291.9 | 333.3 |
| OPM % | 28.51% | 21.56% | 18.89% | 30.25% | 27.08% | 27.67% | 28.3% | 31.83% | 30.75% | 34.2% |
| Other Income | 12.1 | 38.1 | 53.7 | 28.2 | -135.2 | 32.2 | 35.6 | 39.2 | 35.1 | 40.7 |
| Interest | 0.1 | 0.7 | 0.3 | 0.4 | 0.3 | 0.8 | 0.4 | 0.3 | 0.1 | 0.6 |
| Depreciation | 16.4 | 17.2 | 16.4 | 18.1 | 17.1 | 18.1 | 16.4 | 16.9 | 18.8 | 14.7 |
| Profit before tax | 235.6 | 179.6 | 163.7 | 299.2 | 228.7 | 268.2 | 249.4 | 339.1 | 308.1 | 358.7 |
| Tax % | -26.6% | -29.8% | -26.9% | -27.3% | -30.1% | -28.1% | 26.9% | -26.6% | -25.4% | -26.7% |
| Net Profit | 164.6 | 133.4 | 132.3 | 217.5 | 45.7 | 194.5 | 182.3 | 252.5 | 229.9 | 262.9 |
| EPS in Rs | 9.71 | 7.88 | 7.81 | 12.84 | 2.7 | 11.48 | 10.76 | 14.91 | 13.57 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 3% |
| 3 Years: | 5% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 36% |
| 3 Years: | -18% |
| TTM: | 41% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 17% |
| 3 Years: | 25% |
| 1 Year: | 22% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 3% |
| 3 Years: | 5% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 36% |
| 3 Years: | -18% |
| TTM: | 41% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 17% |
| 3 Years: | 25% |
| 1 Year: | 22% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|